Patent and Pharma Update, January 2017

Our regular patent and pharma update aims to keep you informed of recent developments in United Kingdom and European law relating to patents and the pharmaceutical industry. 

The UPC may be open for business in 2017 despite Brexit
A look at recent UPC developments following the June 2016 referendum
Read more


How "obvious to try" are routine steps in clinical research?
Examining recent English court decisions on "obvious to try" assessments carried out in the context of clinical trials in the pharmaceutical industry
Read more


A unified standard for the requirement of plausibility across different grounds of patent invalidity
Understanding the meaning of "plausible" in English patent law by referring to the guidance provided in recent case decisions
Read more


Deploying competition law defences in patent infringement
Noting the increasingly vigilant attitude of competition law authorities to look into settlement/licensing agreements and the deployment of competition law defences in English patent trials
Read more


Click here for summary tables with key points from recent court decisions

Read the full patent and pharma update here.

Authors

Sebastian Moore
Sebastian Moore
Partner, London
Email | Profile
+44 20 7466 2801
Rosie Patterson
Rosie Patterson
Senior Associate, London
Email | Profile
+44 20 7466 2448
Krishna Kakkaiyadi
Krishna Kakkaiyadi
Associate (India), London
Email
+44 20 7466 2979
Rachel Montagnon
Rachel Montagnon
Professional Support Consultant, London
Email | Profile
+44 20 7466 2217

Leave a Comment

Filed under EU, Licensing, Patents, Pharma, The Unified Patent Court and the Unitary Patent, UK

Comments are closed.